HS-20093
Phase 3Small molecule
Jiangsu Hansoh Pharmaceutical Co., Ltd.HS-20093 is one of 337 small molecule programs targeting Patients With Advanced Solid Tumors. It is currently in Phase 3.
10
Indications
17
Total Trials
15
Active Trials
336
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Augtyro
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
HS-20093
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 3
Sitravatinib
MMirati Therapeutics Inc.
Phase 3
Anamorelin Hydrochloride
MM.D. Anderson Cancer Center
Phase 3
Remeron
OOrganon and Co
Preclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Treatment
GSKPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Patients With Advanced Solid Tumors4 trials
Small Cell Lung Cancer3 trials
Prostate Cancer2 trials
Osteosarcoma2 trials
5 more indications
Head and Neck Squamous Cell Carcinoma1 trial
Metastatic Colorectal Cancer1 trial
Esophageal Carcinoma1 trial
Soft Tissue Sarcoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HS-20093. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details